12:00 AM
 | 
Aug 10, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Contusugene ladenovec regulatory update

EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >